Key result
This is an editorial introducing a series of contributions on pharmacology and therapeutics pertinent to coronary artery disease.
Answers are grounded in this paper and cite their sources.
An editorial introduction to a series of articles on pharmacology and therapeutics in coronary artery disease.
Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA Correspondence to Dr John D. Rutherford, Division of Cardiology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, NB11.200, Dallas, TX 75235-8573, USA. Tel: +1 214 648 2515; fax: +1 214 648 6783; e-mail: [email protected] The Editor and Associate Editors are pleased that our readership will have the opportunity to benefit from a series of contributions by Dr John Rutherford addressing current issues in pharmacology and therapeutics pertinent to coronary artery disease. We are pleased that Dr Rutherford will provide authoritative perspectives on topics of immediate interest on a regular basis.
No takes yet. Share an insight, caveat, or question.
John D. Rutherford (2001) conducted an editorial in coronary artery disease. This is an editorial introducing a series of contributions on pharmacology and therapeutics pertinent to coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: